Health Care [ 2/12 ] | Life Sciences Tools & Services [ 12/73 ]
NASDAQ | Common Stock
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States.
The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice.
It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies.
In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies.
It markets its products through internet and sales force to pharmaceutical and biotechnology companies.
The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011.
Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Sep 9, 25 | 0.02 Decreased by -81.82% | 0.06 Decreased by -66.67% |
| Jul 23, 25 | -0.07 Decreased by -800.00% | 0.06 Decreased by -216.67% |
| Mar 10, 25 | 0.33 Increased by +306.25% | -0.01 Increased by +3.40 K% |
| Dec 10, 24 | 0.05 Increased by +133.33% | 0.01 Increased by +400.00% |
| Sep 11, 24 | 0.11 Increased by +157.89% | -0.03 Increased by +466.67% |
| Jul 18, 24 | 0.01 Increased by +105.26% | -0.16 Increased by +106.25% |
| Mar 12, 24 | -0.16 Increased by +11.11% | -0.06 Decreased by -166.67% |
| Dec 12, 23 | -0.15 Decreased by -12.40 K% | -0.17 Increased by +11.76% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jul 31, 25 | 13.99 M Decreased by -0.47% | -466.00 K Decreased by -135.49% | Decreased by -3.33% Decreased by -135.66% |
| Apr 30, 25 | 12.36 M Decreased by -11.76% | -1.83 M Decreased by -1.58 K% | Decreased by -14.84% Decreased by -1.81 K% |
| Jan 31, 25 | 17.04 M Increased by +41.77% | 4.50 M Increased by +277.67% | Increased by +26.38% Increased by +225.32% |
| Oct 31, 24 | 13.49 M Increased by +16.56% | 728.00 K Increased by +135.15% | Increased by +5.40% Increased by +130.16% |
| Jul 31, 24 | 14.06 M Increased by +11.94% | 1.31 M Increased by +151.17% | Increased by +9.34% Increased by +145.71% |
| Apr 30, 24 | 14.00 M Increased by +7.11% | -109.00 K Increased by +95.74% | Decreased by -0.78% Increased by +96.03% |
| Jan 31, 24 | 12.02 M Decreased by -5.90% | -2.53 M Decreased by -3.73% | Decreased by -21.05% Decreased by -10.24% |
| Oct 31, 23 | 11.57 M Decreased by -18.96% | -2.07 M Decreased by -12.84 K% | Decreased by -17.90% Decreased by -15.87 K% |